Akin Gump Advises Baker Bros. in Leap Therapeutics Investment

January 8, 2020

Reading Time : 1 min

Contact:

Jacinta O'Shea-Ramdeholl

Director of Communications

Scott Wasserman

Senior Media Relations Manager

(New York) – Akin Gump advised Baker Bros. Advisors LP in the purchase by its affiliates of Series A mandatorily convertible preferred stock of Leap Therapeutics, Inc. Baker Bros. acted as the lead investor in the transaction. 

Upon approval by the Leap stockholders, the Series A mandatorily convertible preferred stock will automatically convert into pre-funded warrants to purchase 14,218,010 shares of Leap common stock. Upon stockholder approval and conversion of the preferred stock, Baker Bros. will also receive warrants to purchase up to an equal number of shares of common stock.

The Akin Gump team advising Baker Bros. was led by corporate practice head Jeffrey Kochian. He was joined by counsel Alyssa Dossick, Anthony Ameduri and Yehuda Raskin as well as investment management partner Jason Daniel and tax partner Olivier De Moor.

Akin Gump Strauss Hauer & Feld LLP is a leading international law firm with more than 1,000 lawyers and advisors in offices throughout the United States, Europe, Asia and the Middle East.

# # #

Share This Insight

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.